NASDAQ · KTTA
Pasithea Therapeutics Corp.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for KTTA: Nov 12, 2026
Pasithea Therapeutics Corp. Common Stock is estimated to report earnings on 11/12/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 1 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.21. The reported EPS for the same quarter last year was $-0.41.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.21 | $-0.21 | $-0.21 | 1 |
| Dec 2026 | $-0.25 | $-0.25 | $-0.25 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · RTTNews · Fintel · Quiver Quantitative- Zacks · Jul 20, 5:03 AM EDTNew Strong Buy Stocks for July 20thKTTA, NTRS, YEXT, AEHR and STT have been added to the Zacks Rank #1 (Strong Buy) List on July 20, 2026.
- Zacks · Jun 10, 9:55 AM EDTPasithea Therapeutics (KTTA) Could Find a Support Soon, Here's Why You Should Buy the Stock NowPasithea Therapeutics (KTTA) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential fo
- RTTNews · Jun 2, 11:30 AM EDTPasithea's PAS-004 Receives FDA Orphan Drug Designation In Treating AL. Sclerosis(RTTNews) – Pasithea Therapeutics Corp. (KTTA), a clinical-stage biotechnology company, announced it has received Orphan Drug Designation for PAS-004 in treatment of Amyotrophic Lateral Sclerosis by the U.S Food and Drug Administration or FDA.
- RTTNews · Jun 2, 7:21 AM EDTPasithea Therapeutics' PAS-004 Receives FDA Orphan Drug Designation For ALS(RTTNews) – Pasithea Therapeutics Corp. (KTTA) on Tuesday said the U.S. Food and Drug Administration has granted Orphan Drug Designation to its lead candidate, PAS-004, for the treatment of Amyotrophic Lateral Sclerosis (ALS), a progressive neurodegenerative disease that affects
- RTTNews · May 4, 7:37 AM EDTPasithea Therapeutics Appoints Kartik Krishnan As CMO(RTTNews) – Pasithea Therapeutics Corporation (KTTA) said on Monday that it has appointed Kartik Krishnan as chief medical officer with effect from May 1.
- RTTNews · Apr 20, 7:56 AM EDTPasithea Wins FDA Rare Pediatric Disease Status For PAS-004 To Treat Neurofibromatosis Type 1(RTTNews) – Pasithea Therapeutics Corp. (KTTA) on Monday said the U.S. Food and Drug Administration has granted Rare Pediatric Disease Designation to PAS-004 for the treatment of Neurofibromatosis Type 1 (NF1), a rare genetic disorder.
- Fintel · Dec 20, 8:48 PM ESTPasithea Therapeutics (KTTA) Price Target Increased by 50.00% to 3.06The average one-year price target for Pasithea Therapeutics (NasdaqCM:KTTA) has been revised to $3.06 / share. This is an increase of 50.00% from the prior estimate of $2.04 dated August 1, 2023. The price target is an average of many targets provided by analy
- Fintel · Dec 8, 2:23 PM ESTHC Wainwright & Co. Initiates Coverage of Pasithea Therapeutics (KTTA) with Buy RecommendationFintel reports that on December 8, 2025, HC Wainwright & Co. initiated coverage of Pasithea Therapeutics (NasdaqCM:KTTA) with a Buy recommendation. Analyst Price Forecast Suggests 80.53% Upside
- RTTNews · Dec 1, 4:18 AM ESTPasithea Prices $60 Mln Offering To Advance PAS-004 And Broader Pipeline(RTTNews) – Shares of Pasithea Therapeutics Corp. (KTTA) rose up to 38% after the company announced it has priced a $60 million public offering of 80 million shares of common stock at $0.75 per share.
- RTTNews · Nov 28, 2:32 PM ESTPasithea Therapeutics Shares Surge Nearly 39% After $60 Mln Equity Raise(RTTNews) – Pasithea Therapeutics Corp. (KTTA) gained 38.68%, rising $0.41 to $1.47, after the company announced it priced a $60 million public offering, issuing 80 million shares (or equivalent pre-funded warrants) at $0.75 per share.
- RTTNews · Nov 28, 10:14 AM ESTPasithea Therapeutics Prices $60 Mln Public Offering To Advance MEK Inhibitor, Stock Up(RTTNews) – Pasithea Therapeutics Corp. (KTTA) announced on Friday that it has set a price for a public offering of 80 million shares at $0.75 each, which should bring in around $60 million to help fund the development of their main product, PAS-004.
- Quiver Quantitative · Jun 11, 7:14 AM EDTPasithea Therapeutics Appoints Dr. James Lee to Scientific Advisory Board to Advance PAS-004 Development for Inflammatory DiseasesPasithea Therapeutics appoints Dr. James Lee to its advisory board to advance PAS-004 for treating inflammatory diseases.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Pasithea Therapeutics Corp. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.